New Drug Review System to be revamped.

Published: 2003-04-21 06:59:00

Updated: 2003-04-21 06:59:00

The KFDA plans to revamp the new drug review system by intensifying the pre-review controls and the obligation compliances through the working guideline revision. The KFDA has admitted the review system unnecessary and the number of supervisory activities appeared negligible mainly due to the lac...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK